Romosozumab

Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis[1][2].

Product Specifications

CAS Number

[909395-70-6]

Product Name Alternative

AMG-785; CDP-7851

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/romosozumab.html

Purity

99.11

Solubility

H2O

Smiles

[Romosozumab]

Molecular Weight

(146.32 kDa)

References & Citations

[1]Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37 (11) :845-855.|[2]Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32 (4) :788-801.